Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy”

28 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 28 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07659704
What this trial is testing

CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus

Who this might be right for
Lupus Erythematosus, Systemic
University of Sao Paulo 16
Very early researchLooking for participantsNCT07350837
What this trial is testing

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

Who this might be right for
Highly Sensitized Patients Awaiting Kidney Transplant
Tongji Hospital 12
Not applicableActive Not RecruitingNCT05987527
What this trial is testing

Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

Who this might be right for
Kidney Transplant RejectionEnd Stage Renal Disease
Sangamo Therapeutics 11
Not applicableLooking for participantsNCT05146336
What this trial is testing

CytOSorb TreatMent Of Critically Ill PatientS Registry

Who this might be right for
Septic ShockAcute Respiratory Distress SyndromeTrauma+15 more
CytoSorbents, Inc 3,000
Early research (Phase 1)Looking for participantsNCT06305299
What this trial is testing

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Who this might be right for
Ovary NeoplasmOvarian CancerEpithelial Ovarian Cancer+1 more
UNC Lineberger Comprehensive Cancer Center 27
Early research (Phase 1)Looking for participantsNCT07266181
What this trial is testing

Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

Who this might be right for
Refractory Membranous Nephropathy
The First Affiliated Hospital of Air Force Medicial University 5
Early research (Phase 1)WithdrawnNCT06842589
What this trial is testing

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

Who this might be right for
Multi-Drug Resistant Nephrotic SyndromeCAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine
Testing effectiveness (Phase 2)Active Not RecruitingNCT06480565
What this trial is testing

A Phase 1/2 Trial of ADI-270 in ccRCC

Who this might be right for
Clear Cell Renal Cell Carcinoma
Adicet Therapeutics 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05982275
What this trial is testing

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

Who this might be right for
Multiple MyelomaAllogeneic Stem Cell Transplantation
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 25
Very early researchNot Yet RecruitingNCT07423572
What this trial is testing

Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)

Who this might be right for
Refractory Idiopathic Membranous Nephropathy
The First Affiliated Hospital of Zhejiang Chinese Medical University 18
Early research (Phase 1)Ended earlyNCT03960060
What this trial is testing

CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

Who this might be right for
Solid TumorSoft Tissue SarcomaGastric Cancer+2 more
Shanghai PerHum Therapeutics Co., Ltd. 9
Not applicableUnknownNCT05752877
What this trial is testing

Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma

Who this might be right for
Advanced GliomaComplication of Chimeric Antigen Receptor (CAR-T) Cell Therapy
Second Affiliated Hospital of Soochow University 12
Testing effectiveness (Phase 2)Ended earlyNCT05938725
What this trial is testing

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Who this might be right for
Lupus NephritisLupus Nephritis - World Health Organization (WHO) Class IIILupus Nephritis - WHO Class IV
Kyverna Therapeutics 6
Testing effectiveness (Phase 2)Looking for participantsNCT06897930
What this trial is testing

Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Who this might be right for
Lupus Erythematosus, Systemic
AstraZeneca 150
Not applicableUnknownNCT05190653
What this trial is testing

Early Integration of Palliative and Supportive Care in Cellular Therapy

Who this might be right for
LeukemiaLymphomaMultiple Myeloma+3 more
Alberta Health Services, Calgary 152
Testing effectiveness (Phase 2)Looking for participantsNCT05686226
What this trial is testing

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Who this might be right for
Cervical CancerThroat CancerOropharynx Cancer+18 more
Christian Hinrichs 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07729826
What this trial is testing

C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy

Who this might be right for
Lupus Nephritis (LN)Systemic Lupus Erythematosus (SLE)Autoimmune Diseases
AbelZeta Inc. 50
Early research (Phase 1)Temporarily pausedNCT07181720
What this trial is testing

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Lung CancerAnaplastic Thyroid Carcinomas+3 more
Chongqing Precision Biotech Co., Ltd 90
Early research (Phase 1)Looking for participantsNCT07115745
What this trial is testing

Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Who this might be right for
Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 125
Testing effectiveness (Phase 2)Study completedNCT04817774
What this trial is testing

Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients

Who this might be right for
Kidney Transplant RejectionEnd Stage Renal Disease
Sangamo Therapeutics 26
Next Page